CastleArk Alternatives’s Pfizer PFE Stock Holding History

CastleArk Alternatives’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,500	Closed	-$280K	–	214
2021 Q3	$280K	Buy	+6,500	New	+$288K	0.01%	286

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CastleArk Alternatives's PFE Position: Q4 2021 in Review

CastleArk Alternatives sold out of Pfizer (PFE) in Q4 2021, closing a stake of 6,500 shares — an estimated $280K sold.

CastleArk Alternatives first reported a position in PFE in Q3 2021 and held it in 1 quarter. The position peaked at $280K in Q3 2021. 3,262 funds tracked by Wall St. Rank hold PFE as of Q4 2021.

CastleArk Alternatives reported no remaining Pfizer position as of Q4 2021 after selling out during the quarter.
CastleArk Alternatives sold 6,500 Pfizer shares in Q4 2021, an estimated $280K.
CastleArk Alternatives first reported a position in Pfizer in Q3 2021 and held it in 1 quarter.
CastleArk Alternatives's Pfizer position peaked at $280K in Q3 2021.
3,262 funds tracked by Wall St. Rank held Pfizer as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.